Skip to main content

Advertisement

SpringerLink
Log in

Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects

  • Liver (S Cotler and E Kallwitz, Section Editors)
  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Purpose of review

The purpose of this study is to analyze the current evidence regarding the use of statins in patients with chronic liver disease and cirrhosis.

Recent findings

Chronic liver disease (CLD), cirrhosis, and its complications, including hepatocellular carcinoma (HCC), are significant public health problems. The use of statins in patients with CLD has been a matter of concern, and physicians are often reluctant to its prescription in these patients. This mainly relates to the potential occurrence of drug-induced liver injury. However, newer evidence from pre-clinical and clinical research has shown that statins are drugs with a potentially beneficial impact on the natural history of cirrhosis, on portal hypertension, and in HCC prevention.

Summary

In this review, we summarize current evidence regarding the influence of statins in endothelial dysfunction in CLD, their ability to modulate hepatic fibrogenesis, and their vasoprotective effects in portal hypertension; we also focus on existing data about the impact of statins in cirrhosis development, progression, and complications and critically assess the current concerns about its use in patients with CLD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •Of importance ••Of major importance

  1. GBD 2015 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1603–58.

    Article  Google Scholar 

  2. Berzigotti A, Erice E, Gilabert R, Reverter E, Abraldes JG, García-Pagan JC, et al. Cardiovascular risk factors and systemic endothelial function in patients with cirrhosis. Am J Gastroenterol. 2013;108(1):75–82.

    Article  CAS  PubMed  Google Scholar 

  3. Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications. J Hepatol. 2016;65(2):425–43.

    Article  CAS  PubMed  Google Scholar 

  4. Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US preventive services task force. JAMA. 2016;316(19):2008–24.

    Article  PubMed  Google Scholar 

  5. Shalev V, Chodick G, Silber H, Kokia E, Jan J, Heymann AD. Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med. 2009;169(3):260–8.

    Article  PubMed  Google Scholar 

  6. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532–61.

    Article  CAS  PubMed  Google Scholar 

  7. Blaha MJ, Martin SS. How do statins work?: changing paradigms with implications for statin allocation. J Am Coll Cardiol. 2013;62(25):2392–4.

    Article  PubMed  Google Scholar 

  8. •• Bays H, Cohen DE, Chalasani N, Harrison SA. The National Lipid Association’s Statin Safety Task Force. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S47–57. Provides recommendations for statins use and monitoring in healthy patients and CLD patients.

    Article  PubMed  Google Scholar 

  9. Schierwagen R, Uschner FE, Magdaleno F, Klein S, Trebicka J. Rationale for the use of statins in liver disease. Am J Physiol Gastrointest Liver Physiol. 2017;312(5):G407–12.

    Article  PubMed  Google Scholar 

  10. Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014;88:3–11.

    Article  CAS  PubMed  Google Scholar 

  11. Germershausen JI, Hunt VM, Bostedor RG, Bailey PJ, Karkas JD, Alberts AW. Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochem Biophys Res Commun. 1989;158(3):667–75.

    Article  CAS  PubMed  Google Scholar 

  12. Arnaboldi L, Corsini A. Do structural differences in statins correlate with clinical efficacy? Curr Opin Lipidol. 2010;21(4):298–304.

    Article  CAS  PubMed  Google Scholar 

  13. Desai CS, Martin SS, Blumenthal RS. Non-cardiovascular effects associated with statins. BMJ. 2014;349:g3743.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Trebicka J, Schierwagen R. Statins, Rho GTPases and KLF2: new mechanistic insight into liver fibrosis and portal hypertension. Gut. 2015;64(9):1349–50.

    Article  CAS  PubMed  Google Scholar 

  15. Izadpanah R, Schächtele DJ, Pfnür AB, Lin D, Slakey DP, Kadowitz PJ, et al. The impact of statins on biological characteristics of stem cells provides a novel explanation for their pleiotropic beneficial and adverse clinical effects. Am J Physiol, Cell Physiol. 2015;309(8):C522–31.

    Article  CAS  PubMed  Google Scholar 

  16. Gracia-Sancho J, Russo L, García-Calderó H, García-Pagán JC, García-Cardeña G, Bosch J. Endothelial expression of transcription factor Kruppel-like factor 2 and its vasoprotective target genes in the normal and cirrhotic rat liver. Gut. 2011;60(4):517–24.

    Article  CAS  PubMed  Google Scholar 

  17. • Marrone G, Maeso-Díaz R, García-Cardena G, Abraldes JG, García-Pagán JC, Bosch J, et al. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. Gut. 2015;64(9):1434–43. Describes the benefitial effects of KFL2 induction by simvastatin in an animal model of liver fibrosis and portal hypertension.

    Article  CAS  PubMed  Google Scholar 

  18. Marrone G, Russo L, Rosado E, Hide D, García-Cardeña G, García-Pagán JC, et al. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins. J Hepatol. 2013;58(1):98–103.

    Article  CAS  PubMed  Google Scholar 

  19. Russo L, Gracia-Sancho J, García-Calderó H, Marrone G, García-Pagán JC, García-Cardeña G, et al. Addition of simvastatin to cold storage solution prevents endothelial dysfunction in explanted rat livers. Hepatology. 2012;55(3):921–30.

    Article  CAS  PubMed  Google Scholar 

  20. Chong L-W, Hsu Y-C, Lee T-F, Lin Y, Chiu Y-T, Yang K-C, et al. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells. BMC Gastroenterol. 2015;15:22.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Klein S, Klösel J, Schierwagen R, Körner C, Granzow M, Huss S, et al. Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats. Lab Investig. 2012;92(10):1440–50.

    Article  CAS  PubMed  Google Scholar 

  22. Rombouts K, Kisanga E, Hellemans K, Wielant A, Schuppan D, Geerts A. Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells. J Hepatol. 2003;38(5):564–72.

    Article  CAS  PubMed  Google Scholar 

  23. Trebicka J, Hennenberg M, Odenthal M, Shir K, Klein S, Granzow M, et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol. 2010;53(4):702–12.

    Article  CAS  PubMed  Google Scholar 

  24. Shirin H, Sharvit E, Aeed H, Gavish D, Bruck R. Atorvastatin and rosuvastatin do not prevent thioacetamide induced liver cirrhosis in rats. World J Gastroenterol. 2013;19(2):241–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Uschner FE, Ranabhat G, Choi SS, Granzow M, Klein S, Schierwagen R, et al. Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension. Sci Rep. 2015;5:14573.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Trebicka J, Hennenberg M, Laleman W, Shelest N, Biecker E, Schepke M, et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology. 2007;46(1):242–53.

    Article  CAS  PubMed  Google Scholar 

  27. Arab JP, Shah VH. Statins and portal hypertension: a tale of two models. Hepatology. 2016;63(6):2044–7.

    Article  PubMed  Google Scholar 

  28. Hsu S-J, Wang S-S, Hsin I-F, Huang H-C, Lee F-Y, Lee J-Y, et al. Effects of simvastatin on the portal-systemic collateral vascular response to endothelin-1 and shunting degree in portal hypertensive rats. Scand J Gastroenterol. 2013;48(7):831–8.

    Article  CAS  PubMed  Google Scholar 

  29. Huang H-C, Wang S-S, Lee J-Y, Chen Y-C, Lee F-Y, Lin H-C, et al. Simvastatin effects on portal-systemic collaterals of portal hypertensive rats. J Gastroenterol Hepatol. 2010;25(8):1401–9.

    Article  CAS  PubMed  Google Scholar 

  30. Chang C-C, Wang S-S, Huang H-C, Lee J-Y, Lee F-Y, Lin H-C, et al. Pravastatin administration does not induce detrimental effects on hemodynamics and collaterals of portal hypertensive rats. J Gastroenterol Hepatol. 2010;25(8):1394–400.

    Article  CAS  PubMed  Google Scholar 

  31. Rodríguez S, Raurell I, Torres-Arauz M, García-Lezana T, Genescà J, Martell M. A nitric oxide-donating statin decreases portal pressure with a better toxicity profile than conventional statins in cirrhotic rats. Sci Rep. 2017;7:40461.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Nie L, Imamura M, Itoh H, Ueno H. Pitavastatin enhances the anti-fibrogenesis effects of candesartan, an angiotensin II receptor blocker, on CCl4-induced liver fibrosis in rats. J UOEH. 2004;26(2):165–77.

    Article  CAS  PubMed  Google Scholar 

  33. El-Ashmawy NE, El-Bahrawy HA, Shamloula MM, Ibrahim AO. Antifibrotic effect of AT-1 blocker and statin in rats with hepatic fibrosis. Clin Exp Pharmacol Physiol. 2015;

  34. Nseir W, Mahamid M. Statins in nonalcoholic fatty liver disease and steatohepatitis: updated review. Curr Atheroscler Rep. 2013;15(3):305.

    Article  PubMed  Google Scholar 

  35. Schierwagen R, Maybüchen L, Hittatiya K, Klein S, Uschner FE, Braga TT, et al. Statins improve NASH via inhibition of RhoA and Ras. Am J Physiol Gastrointest Liver Physiol. 2016;311(4):G724–33.

    Article  PubMed  Google Scholar 

  36. Park HS, Jang JE, Ko MS, Woo SH, Kim BJ, Kim HS, et al. Statins increase mitochondrial and peroxisomal fatty acid oxidation in the liver and prevent non-alcoholic steatohepatitis in mice. Diabetes Metab J. 2016;40(5):376–85.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Okada Y, Yamaguchi K, Nakajima T, Nishikawa T, Jo M, Mitsumoto Y, et al. Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats. Liver Int. 2013;33(2):301–11.

    Article  CAS  PubMed  Google Scholar 

  38. Kamada Y, Kiso S, Yoshida Y, Chatani N, Kizu T, Hamano M, et al. Estrogen deficiency worsens steatohepatitis in mice fed high-fat and high-cholesterol diet. Am J Physiol Gastrointest Liver Physiol. 2011;301(6):G1031–43.

    Article  CAS  PubMed  Google Scholar 

  39. Kamada Y, Kiso S, Yoshida Y, Chatani N, Kizu T, Hamano M, et al. Pitavastatin ameliorated the progression of steatohepatitis in ovariectomized mice fed a high fat and high cholesterol diet. Hepatol Res. 2013;43(4):401–12.

    Article  CAS  PubMed  Google Scholar 

  40. Wu W, Zhao L, Yang P, Zhou W, Li B, Moorhead JF, et al. Inflammatory stress sensitizes the liver to atorvastatin-induced injury in ApoE−/− mice. PLoS One. 2016;11(7):e0159512.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Kamisako T, Adachi Y. Marked improvement in cholestasis and hypercholesterolemia with simvastatin in a patient with primary biliary cirrhosis. Am J Gastroenterol. 1995;90(7):1187–8.

    CAS  PubMed  Google Scholar 

  42. Stojakovic T, Claudel T, Putz-Bankuti C, Fauler G, Scharnagl H, Wagner M, et al. Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. Atherosclerosis. 2010;209(1):178–83.

    Article  CAS  PubMed  Google Scholar 

  43. Cash WJ, O’Neill S, O’Donnell ME, McCance DR, Young IS, McEneny J, et al. Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis. Liver Int. 2013;33(8):1166–74.

    Article  CAS  PubMed  Google Scholar 

  44. Henderson LM, Patel S, Giordano TP, Green L, El-Serag HB. Statin therapy and serum transaminases among a cohort of HCV-infected veterans. Dig Dis Sci. 2010;55(1):190–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Simon TG, King LY, Zheng H, Chung RT. Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. J Hepatol. 2015;62(1):18–23.

    Article  CAS  PubMed  Google Scholar 

  46. Butt AA, Yan P, Bonilla H, Abou-Samra A-B, Shaikh OS, Simon TG, et al. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: results from ERCHIVES. Hepatology. 2015;62(2):365–74.

    Article  CAS  PubMed  Google Scholar 

  47. Yang Y-H, Chen W-C, Tsan Y-T, Chen M-J, Shih W-T, Tsai Y-H, et al. Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection. J Hepatol. 2015;63(5):1111–7.

    Article  CAS  PubMed  Google Scholar 

  48. • Huang Y-W, Lee C-L, Yang S-S, Fu S-C, Chen Y-Y, Wang T-C, et al. Statins reduce the risk of cirrhosis and its decompensation in chronic hepatitis B patients: a nationwide cohort study. Am J Gastroenterol. 2016;111(7):976–85. Study from a large cohort of patients with chronic hepatitis B showing a dose-dependent reduction in the risk of cirrhosis and its decompensation.

  49. Oni ET, Sinha P, Karim A, Martin SS, Blaha MJ, Agatston AS, et al. Statin use is not associated with presence of and severity of nonalcoholic fatty liver disease. Arch Med Res. 2014;45(1):52–7.

    Article  CAS  PubMed  Google Scholar 

  50. Dongiovanni P, Petta S, Mannisto V, Mancina RM, Pipitone R, Karja V, et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol. 2015;63(3):705–12.

    Article  CAS  PubMed  Google Scholar 

  51. Kumar S, Grace ND, Qamar AA. Statin use in patients with cirrhosis: a retrospective cohort study. Dig Dis Sci. 2014;59(8):1958–65.

    Article  CAS  PubMed  Google Scholar 

  52. • Mohanty A, Tate JP, Garcia-Tsao G. Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis. Gastroenterology. 2016;150(2):430–40.e1. Retrospective database analysis including a large number of patients showing an effect of statins in cirrhosis decompensation and death.

    Article  CAS  PubMed  Google Scholar 

  53. • ChangF-M, WangY-P, LangH-C, TsaiC-F, HouM-C, LeeF-Y, et al. Statins decrease the risk of decompensation in HBV- and HCV-related cirrhosis: a population-based study. Hepatology. 2017. Epidemiological study suggesting that the effect of statins in cirrhosis progression and complications is related to etiology.

  54. Motzkus-Feagans C, Pakyz AL, Ratliff SM, Bajaj JS, Lapane KL. Statin use and infections in veterans with cirrhosis. Aliment Pharmacol Ther. 2013;38(6):611–8.

    Article  CAS  PubMed  Google Scholar 

  55. Zafra C, Abraldes JG, Turnes J, Berzigotti A, Fernández M, Garca-Pagán JC, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology. 2004;126(3):749–55.

    Article  CAS  PubMed  Google Scholar 

  56. Abraldes JG, Albillos A, Bañares R, Turnes J, González R, García-Pagán JC, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology. 2009;136(5):1651–8.

    Article  CAS  PubMed  Google Scholar 

  57. Pollo-Flores P, Soldan M, Santos UC, Kunz DG, Mattos DE, da Silva AC, et al. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial. Dig Liver Dis. 2015;47(11):957–63.

    Article  CAS  PubMed  Google Scholar 

  58. •• Abraldes JG, Villanueva C, Aracil C, Turnes J, Hernandez-Guerra M, Genesca J, et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology. 2016;150(5):1160–70.e3. Randomized controlled trial evaluating the benefit of addition of simvastatin to standard therapy in prevention of recurrent variceal bledding.

    Article  CAS  PubMed  Google Scholar 

  59. •• KimRG, LoombaR, ProkopLJ, SinghS. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017. Quantitative summary of the risk and benefits of the use of statins in CLD patients.

  60. McGlynn KA, Divine GW, Sahasrabuddhe VV, Engel LS, VanSlooten A, Wells K, et al. Statin use and risk of hepatocellular carcinoma in a U.S. population. Cancer Epidemiol. 2014;38(5):523–7.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Tsan Y-T, Lee C-H, Ho W-C, Lin M-H, Wang J-D, Chen P-C. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J Clin Oncol. 2013;31(12):1514–21.

    Article  PubMed  Google Scholar 

  62. •• Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology. 2013;144(2):323–32. Quantitative summary of the effect of statins in HCC in CLD patients.

    Article  CAS  PubMed  Google Scholar 

  63. Demyen M, Alkhalloufi K, Pyrsopoulos NT. Lipid-lowering agents and hepatotoxicity. Clin Liver Dis. 2013;17(4):699–714. x

    Article  PubMed  Google Scholar 

  64. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97(8A):52C–60C.

    Article  CAS  PubMed  Google Scholar 

  65. Thatishetty AV, Agresti N, O’Brien CB. Chemotherapy-induced hepatotoxicity. Clin Liver Dis. 2013;17(4):671–86. ix

    Article  PubMed  Google Scholar 

  66. Henninger C, Huelsenbeck J, Huelsenbeck S, Grösch S, Schad A, Lackner KJ, et al. The lipid lowering drug lovastatin protects against doxorubicin-induced hepatotoxicity. Toxicol Appl Pharmacol. 2012;261(1):66–73.

    Article  CAS  PubMed  Google Scholar 

  67. Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012;56(2):374–80.

    Article  PubMed  Google Scholar 

  68. • Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015;148(7):1340–52.e7. Data from the US registry of drug induced liver injury.

    Article  PubMed  PubMed Central  Google Scholar 

  69. • Medina-Caliz I, Robles-Diaz M, Garcia-Muñoz B, Stephens C, Ortega-Alonso A, Garcia-Cortes M, et al. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. J Hepatol. 2016;65(3):532–42. Data from the Spanish registry of drug induced liver injury.

    Article  CAS  PubMed  Google Scholar 

  70. Slim M, Ruiz-Cabello E, Robles-Díaz M, Lucena MI, Andrade RJ. A new hepatoprotective effect of statins: are they always safe for the liver? Am J Gastroenterol. 2017;112(2):384–5.

    Article  CAS  PubMed  Google Scholar 

  71. Del Ben M, Baratta F, Polimeni L, Pastori D, Loffredo L, Averna M, et al. Under-prescription of statins in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2017;27(2):161–7.

    Article  PubMed  Google Scholar 

  72. Bays H. Statin safety: an overview and assessment of the data—2005. Am J Cardiol. 2006;97(8A):6C–26C.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by grant(s) NIH DK59615 and AA021171 (VHS), the Clinical Core of the Mayo Clinic Center for Cell Signaling in Gastroenterology (P30DK084567). Arab JP was founded by an award from AASLD Foundation (AASLD/LIFER Clinical and Translational Research Fellowship in Liver Diseases 2016). Support from the government of Chile through the Fondo Nacional de Desarrollo Cientıfico y Tecnologico (FONDECYT 1150327 to M.A.) and the Comision Nacional de Investigacion Cientıfica y Tecnologica (grant CONICYTPIA/Basal PFB12, Basal Centre for Excellence in Science and Technology to M.A.) is also acknowledged.

Author information

Authors and Affiliations

  1. Department of Gastroenterology School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

    Jose Ignacio Vargas, Marco Arrese & Juan Pablo Arab

  2. Centro de Envejecimiento y Regeneración (CARE), Departamento de Biología Celular y Molecular, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile

    Marco Arrese

  3. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA

    Vijay H. Shah & Juan Pablo Arab

Authors
  1. Jose Ignacio Vargas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marco Arrese
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vijay H. Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Juan Pablo Arab
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Vijay H. Shah or Juan Pablo Arab.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Liver

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vargas, J.I., Arrese, M., Shah, V.H. et al. Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects. Curr Gastroenterol Rep 19, 43 (2017). https://doi.org/10.1007/s11894-017-0584-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11894-017-0584-7

Keywords

Search

Navigation